AU2013350802B2 - Methods for making conjugates from disulfide-containing proteins - Google Patents

Methods for making conjugates from disulfide-containing proteins

Info

Publication number
AU2013350802B2
AU2013350802B2 AU2013350802A AU2013350802A AU2013350802B2 AU 2013350802 B2 AU2013350802 B2 AU 2013350802B2 AU 2013350802 A AU2013350802 A AU 2013350802A AU 2013350802 A AU2013350802 A AU 2013350802A AU 2013350802 B2 AU2013350802 B2 AU 2013350802B2
Authority
AU
Australia
Prior art keywords
protein
payload
conjugate
functionalized
disulfide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013350802A
Other languages
English (en)
Other versions
AU2013350802A1 (en
Inventor
Qi-Ying Hu
Hidetomo Imase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013350802A1 publication Critical patent/AU2013350802A1/en
Application granted granted Critical
Publication of AU2013350802B2 publication Critical patent/AU2013350802B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0006—Diet or mouth appliances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C5/00—Filling or capping teeth
    • A61C5/90—Oral protectors for use during treatment, e.g. lip or mouth protectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/56—Devices for preventing snoring
    • A61F5/566—Intra-oral devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nursing (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dentistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013350802A 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins Ceased AU2013350802B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731852P 2012-11-30 2012-11-30
US61/731,852 2012-11-30
PCT/IB2013/060427 WO2014083505A1 (en) 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins

Publications (2)

Publication Number Publication Date
AU2013350802A1 AU2013350802A1 (en) 2015-04-09
AU2013350802B2 true AU2013350802B2 (en) 2016-07-14

Family

ID=49726841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013350802A Ceased AU2013350802B2 (en) 2012-11-30 2013-11-26 Methods for making conjugates from disulfide-containing proteins

Country Status (13)

Country Link
US (3) US10022256B2 (enExample)
EP (1) EP2925368B1 (enExample)
JP (1) JP6408480B2 (enExample)
KR (1) KR20150090081A (enExample)
CN (1) CN104853781B (enExample)
AU (1) AU2013350802B2 (enExample)
BR (1) BR112015011317A2 (enExample)
CA (1) CA2888445A1 (enExample)
EA (1) EA201591049A1 (enExample)
ES (1) ES2732574T3 (enExample)
IN (1) IN2015DN02913A (enExample)
MX (1) MX2015006868A (enExample)
WO (1) WO2014083505A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
SG11201600211XA (en) * 2013-07-25 2016-02-26 Novartis Ag Cyclic polypeptides for the treatment of heart failure
TW201518323A (zh) * 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
JP6609563B2 (ja) * 2013-11-26 2019-11-20 ノバルティス アーゲー ケトンで修飾されたポリペプチドをオキシム複合化する方法
US20150182373A1 (en) * 2014-01-02 2015-07-02 DMD Todd D. Morgan Oral Exercise Appliance
EP3145552B1 (en) * 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
WO2016209978A2 (en) 2015-06-22 2016-12-29 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
JP2019522050A (ja) * 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 細胞の枯渇のための組成物および方法
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
KR20200094181A (ko) 2017-11-29 2020-08-06 마젠타 테라퓨틱스 인코포레이티드 Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
EA202191961A1 (ru) 2019-01-16 2021-12-13 Ридженерон Фармасьютикалз, Инк. Способ и система идентификации и количественного определения фрагментации антител
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
EP3972650A2 (en) 2019-05-20 2022-03-30 Novartis AG Antibody drug conjugates having linkers comprising hydrophilic groups
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
KR20230107276A (ko) * 2020-11-09 2023-07-14 가고시마 유니버시티 펩타이드 가교제 및 상기 가교제를 이용하여 가교된 가교 펩타이드
EP4507634A2 (en) * 2022-04-15 2025-02-19 Jeffrey Goldberg Hunger satiating dental appliance
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239110B1 (en) 1990-02-22 2001-05-29 W.R. Grace & Co. -Conn. Synthetic analogs of thrombospondin and therapeutic use thereof
WO1999013063A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders
WO1999013062A1 (en) 1997-09-09 1999-03-18 Nycomed Imaging As Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
ATE500215T1 (de) 2005-11-08 2011-03-15 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
WO2008157380A2 (en) 2007-06-15 2008-12-24 Adherex Technologies Inc. Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
US8680022B2 (en) 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
EP2549276B1 (en) 2009-08-10 2015-02-25 UCL Business PLC Reversible covalent linkage of functional molecules
EP2906598A1 (en) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
DK2920196T3 (da) 2012-11-15 2021-06-14 Univ Brandeis Binding af cysteinrester under anvendelse af cykliske disulfider
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
JP6609563B2 (ja) 2013-11-26 2019-11-20 ノバルティス アーゲー ケトンで修飾されたポリペプチドをオキシム複合化する方法

Also Published As

Publication number Publication date
US20190038444A1 (en) 2019-02-07
CN104853781A (zh) 2015-08-19
JP2015537045A (ja) 2015-12-24
US20150290009A1 (en) 2015-10-15
IN2015DN02913A (enExample) 2015-09-18
CA2888445A1 (en) 2014-06-05
KR20150090081A (ko) 2015-08-05
BR112015011317A2 (pt) 2017-07-11
CN104853781B (zh) 2017-10-24
JP6408480B2 (ja) 2018-10-17
US10667935B2 (en) 2020-06-02
US11311400B2 (en) 2022-04-26
EP2925368A1 (en) 2015-10-07
EP2925368B1 (en) 2019-03-27
ES2732574T3 (es) 2019-11-25
EA201591049A1 (ru) 2015-09-30
WO2014083505A1 (en) 2014-06-05
US20200253768A1 (en) 2020-08-13
MX2015006868A (es) 2015-10-05
US10022256B2 (en) 2018-07-17
AU2013350802A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
AU2013350802B2 (en) Methods for making conjugates from disulfide-containing proteins
EP3074048B1 (en) Methods for oxime conjugation to ketone-modified polypeptides
EP3145552B1 (en) Methods for making conjugates from disulfide-containing proteins
CN111542344B (zh) 包含单分子量聚肌氨酸的配体-药物-缀合物
CN118510515A (zh) 基于哒嗪二酮的双杂环共价连接子及其方法和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired